<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00830414</url>
  </required_header>
  <id_info>
    <org_study_id>LA486</org_study_id>
    <nct_id>NCT00830414</nct_id>
  </id_info>
  <brief_title>Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women</brief_title>
  <official_title>A Pivotal Study to Evaluate the Bioequivalence of 150 mg/1 mL Medroxyprogesterone Acetate Injection in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared the rates and extents of medroxyprogesterone absorption from two&#xD;
      medroxyprogesterone acetate injection formulations following single 150 mg intramuscular (IM)&#xD;
      injections to healthy postmenopausal women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria&#xD;
&#xD;
      Statistical Methods: FDA bioequivalence statistical methods&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">September 2002</completion_date>
  <primary_completion_date type="Actual">September 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC</measure>
    <time_frame>120 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DEPO-PROVERA®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medroxyprogesterone acetate</intervention_name>
    <description>IM Injection</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medroxyprogesterone acetate</intervention_name>
    <description>IM injection</description>
    <arm_group_label>2</arm_group_label>
    <other_name>DEPO-PROVERA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Screening Demographics: All volunteers selected for this study will be healthy&#xD;
             postmenopausal women 45 years of age or older at the time of dosing. The weight range&#xD;
             will not exceed ±20% for height and body frame as per Desirable Weights for Women -&#xD;
             1983 Metropolitan Height and Weight Table.&#xD;
&#xD;
          -  Screening Procedures: Each volunteer will complete the screening process within 28&#xD;
             days prior to period I dosing. Consent documents for both the screening evaluation and&#xD;
             HIV antibody determination will be reviewed, discussed and signed by each potential&#xD;
             participant before full implementation of screening procedures.&#xD;
&#xD;
        Screening will include general observations, physical examination, demographics, medical&#xD;
        and medication history, an electrocardiogram, sitting blood pressure and pulse, respiratory&#xD;
        rate and temperature. The physical examination will include, but may not be limited to, an&#xD;
        evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous&#xD;
        systems.&#xD;
&#xD;
        Screening will include a Gynecological examination (PAP smear, breast) which does not show&#xD;
        clinically relevant findings, e.g. a cytological smear classified according to Papanicolau&#xD;
        (PAP) higher than grade II.&#xD;
&#xD;
        The screening clinical laboratory procedures will include:&#xD;
&#xD;
          -  HEMATOLOGY: hematocrit, hemoglobin, WBC count with differential, RBC count, platelet&#xD;
             count&#xD;
&#xD;
          -  CLINICAL CHEMISTRY: serum creatinine, BUN, glucose, AST(GOT), ALT(GPT), albumin, total&#xD;
             bilirubin, total protein, and alkaline phosphatase&#xD;
&#xD;
          -  HIV antibody, hepatitis GB surface antigen, and anti hepatitis C virus screens&#xD;
&#xD;
          -  URINALYSIS: by dipstick; full microscopic examination if dipstick positive&#xD;
&#xD;
          -  URINE DRUG SCREEN: amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine&#xD;
             metabolites, and opiates&#xD;
&#xD;
          -  Ethyl alcohol will be measured using breath test (alcomat)&#xD;
&#xD;
          -  FSH (to verify postmenopausal status)&#xD;
&#xD;
          -  17β-Estradiol (to verify postmenopausal status)&#xD;
&#xD;
          -  SERUM PREGNANCY SCREEN&#xD;
&#xD;
        Is female and:&#xD;
&#xD;
        o Is postmenopausal for at least 1 year and has a serum FSH level greater than or equal to&#xD;
        30 mIU/mL and a serum 17β-estradiol level less than 30 pg/mL.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Volunteers with a recent history of drug or alcohol addiction or abuse.&#xD;
&#xD;
          -  Volunteers with the presence of a clinically significant disorder involving the&#xD;
             cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic,&#xD;
             endocrine, gynecologic or neurologic system(s) or psychiatric disease (as determined&#xD;
             by the clinical investigators or co-investigators).&#xD;
&#xD;
          -  Volunteers whose clinical laboratory test values show clinically relevant deviations&#xD;
             from normal when confirmed on re-examination.&#xD;
&#xD;
          -  Volunteers demonstrating a positive hepatitis B surface antigen screen, a positive&#xD;
             anti HCV screen or a reactive HIV antibody screen.&#xD;
&#xD;
          -  Volunteers demonstrating a positive drug abuse screen when screened for this study.&#xD;
&#xD;
          -  Volunteers demonstrating a positive pregnancy screen.&#xD;
&#xD;
          -  Volunteers with a history of allergic response(s) to medroxyprogesterone acetate or&#xD;
             related drugs.&#xD;
&#xD;
          -  Volunteers with a history of clinically significant allergies including drug&#xD;
             allergies.&#xD;
&#xD;
          -  Volunteers with a history of undiagnosed vaginal bleeding.&#xD;
&#xD;
          -  Volunteers with personal or immediate family (mother, sister, daughter) history of&#xD;
             breast cancer.&#xD;
&#xD;
          -  Volunteers with a history of thromboembolic disorder, thrombophlebitis, or history of&#xD;
             anticoagulant use other than aspirin.&#xD;
&#xD;
          -  Volunteers with a clinically significant illness during the 4 weeks prior to Period I&#xD;
             dosing (as determined by the clinical investigators or co-investigators).&#xD;
&#xD;
          -  Volunteers who currently use tobacco products.&#xD;
&#xD;
          -  Volunteers who have taken any drug known to induce or inhibit hepatic drug metabolism&#xD;
             in the 30 days prior to Period I dosing.&#xD;
&#xD;
          -  Volunteers who report donating greater than 450 mL of blood within 30 days prior to&#xD;
             dosing. All subjects will be advised not to donate blood for four weeks after&#xD;
             completing the study.&#xD;
&#xD;
          -  Volunteers who have donated plasma (e.g. plasmapheresis) within 14 days prior to&#xD;
             dosing. All subjects will be advised not to donate plasma for four weeks after&#xD;
             completing the study.&#xD;
&#xD;
          -  Volunteers who report receiving any investigational drug within 30 days prior to&#xD;
             dosing.&#xD;
&#xD;
          -  Volunteers who report taking any systemic prescription medication in the 14 days prior&#xD;
             to dosing (for hormone replacement therapy (HRT) 4 weeks prior to dosing).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horst Jurgen Heuer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AAI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AAI Deutschland GmbH &amp; Co. KG</name>
      <address>
        <city>Neu-Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>January 26, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2009</study_first_posted>
  <last_update_submitted>January 26, 2009</last_update_submitted>
  <last_update_submitted_qc>January 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

